A new drug delivery system for treatment of disease

US2020023073A1 · US · A1

Patent metadata
FieldValue
Publication numberUS-2020023073-A1
Application numberUS-201716338152-A
CountryUS
Kind codeA1
Filing dateSep 29, 2017
Priority dateSep 29, 2016
Publication dateJan 23, 2020
Grant date

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

The present invention is generally directed to improvements in the treatment of cancer and diseases in the central nervous system. A new drug delivery system is provided, method for producing it and medical uses.

First claim

Opening claim text (preview).

1 . A drug delivery method comprising systemically administering a drug delivery system, and generating an acoustic field at a release site to mediate the delivery of said drug delivery system to a target site, wherein the drug delivery system comprises a gas-filled microbubble, a plurality of nanoparticles associated with the gas-filled microbubble, free nanoparticles, and at least one therapeutic agent associated with at least one of the associated nanoparticles and at least one of the free nanoparticles, wherein the nanoparticles are poly alkyl cyanoacrylate (PACA) nanoparticles. 2 . The drug delivery method according to claim 1 , wherein the nanoparticles associated with the gas-filled microbubble are surface-associated to the gas-filled microbubble. 3 . The drug delivery system according to claim 1 , wherein the at least one therapeutic agent is loaded within the nanoparticles. 4 . (canceled) 5 . (canceled) 6 . (canceled) 7 . The drug delivery method according to claim 1 , wherein the nanoparticles associated with the gas-filled microbubbles stabilizes the microbubbles. 8 . The drug delivery method according to claim 1 , wherein the nanoparticles further compriseing at least one targeting agent. 9 . The drug delivery method according to claim 1 , further comprising a pharmaceutically acceptable carrier. 10 . The drug delivery method according to claim 1 , wherein the nanoparticles further are coated with polyethylene glycol (PEG). 11 . The drug delivery method according to claim 1 , wherein the mean diameter of the gas-filled microbubbles associated with nanoparticles is in the range of 0.5 to 30 □m. 12 . The drug delivery method according to claim 1 , wherein the therapeutic agent is a chemotherapeutic agent or a chemopotentiator. 13 . The drug delivery method according to claim 1 , wherein the gas-filled microbubbles is filled with a gas selected from the group consisting of air, perfluorocarbon, —N 2 , O 2 , and CO 2 . 14 . The drug delivery method according to claim 1 , wherein the acoustic field is generated by ultrasound. 15 . The drug delivery method according to claim 1 , wherein the microbubbles are destroyable upon application of focused ultrasound thereto. 16 . A method for preparing a drug delivery system for use in therapy according to claim 1 , comprising: a) synthesizing the nanoparticles to be loaded with the therapeutic agent; b) adding the nanoparticles to a solution comprising a surface-active substance; and c) mixing the solution of b) with a gas to obtain gas-filled bubbles. 17 . The method according to claim 16 , wherein the microbubbles are stabilized by self-assembly of nanoparticles in a gas-water interface. 18 . (canceled) 19 . The method according to claim 16 , wherein the solution in c) is mixed from 2 seconds to 60 minutes. 20 . The method according to claim 16 , wherein the solution in c) is mixed at 500 to 50,000 rpm. 21 . The method according to claim 16 , wherein the surface-active substance is a serum, a protein, a lipid or a surfactant. 22 . A composition comprising a gas-filled microbubble, a plurality of nanoparticles associated with the microbubble, at least one free nanoparticle, and at least one therapeutic agent associated with at least one of the associated nanoparticles and at least one of the free nanoparticles, wherein the nanoparticles are poly(alkylcyanoacrylate) (PACA) nanoparticles. 23 . The composition according to claim 22 , wherein the plurality of nanoparticles associated with the gas-filled microbubble are surface-associated to the gas-filled microbubble. 24 . The composition according to claims 22 , wherein the one or more therapeutic agents associated with the nanoparticle and microbubble are loaded within the nanoparticles. 25 . (canceled) 26 . (canceled) 27 . The composition according to claim 22 , wherein the plurality of nanoparticles associated with the gas-filled microbubbles stabilizes the microbubbles. 28 . The composition according to claim 22 , wherein the nanoparticles further compriseing at least one targeting agent. 29 . The composition according to claim 22 , further comprising a pharmaceutically acceptable carrier. 30 . The composition according to claim 22 , wherein the nanoparticles further are coated with polyethylene glycol (PEG). 31 . The composition according to claim 22 , wherein the mean diameter of the gas-filled microbubbles associated with a plurality of nanoparticles is in the range of 0.5 to 30 □m. 32 . The composition according to claim 32 , wherein the one or more therapeutic agents are chemotherapeutic agent or a chemopotentiator. 33 . The composition according to claim 22 , wherein the gas-filled microbubbles are filled with a gas selected from the group consisting of air, perfluorocarbon, H 2 , O 2 and CO 2 . 34 . A method of treating cancer or diseases in the central nervous system comprising administering a drug delivery system according to claim 1 to a patient in need thereof.

Assignees

Inventors

Classifications

  • Antineoplastic agents · CPC title

  • having four-membered rings, e.g. taxol · CPC title

  • Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers (A61K9/0026 takes precedence) · CPC title

  • the form being a microcapsule, nanocapsule, microbubble or nanobubble · CPC title

  • using multiple frequencies · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US2020023073A1 cover?
The present invention is generally directed to improvements in the treatment of cancer and diseases in the central nervous system. A new drug delivery system is provided, method for producing it and medical uses.
Who is the assignee on this patent?
Sintef Tto As
What technology area does this patent fall under?
Primary CPC classification A61K47/6933. Mapped technology areas include Human Necessities.
When was this patent published?
Publication date Thu Jan 23 2020 00:00:00 GMT+0000 (Coordinated Universal Time) (A1). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).